P2Y 12 ADP receptor antagonists after percutaneous coronary interventions P2Y 12 -ADP-Rezeptorantagonisten nach perkutanen Koronarinterventionen

Author： Trenk Dietmar  

Publisher： Govi-Verlag

ISSN： 2195-2175

Source： PHARMAKON, Vol.1, Iss.1, 2013-01, pp. : 53-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development

By Angiolillo Dominick J   Suryadevara Siva   Capranzano Piera   Bass Theodore A  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2893-2900

Informa Healthcare

Access to resources Recommend Favorite

Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists

By  

Current Drug Targets, Vol. 12, Iss. 12, 2011-11 ,pp. : 1805-1812

Bentham Science Publishers

Access to resources Recommend Favorite

P2Y12 Receptor Antagonists: Which One to Choose? A Systematic Review and Meta-Analysis

By  

Current Pharmaceutical Design, Vol. 22, Iss. 29, 2016-09 ,pp. : 4568-4576

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Prasugrel, a Novel P2Y 12 Receptor Antagonist, in the Management of Acute Coronary Syndromes

By Baker William L.   White C. Michael  

American Journal of Cardiovascular Drugs, Vol. 9, Iss. 4, 2009-08 ,pp. : 213-229

Adis International

Access to resources Recommend Favorite

Biology and Pharmacology of the Platelet P2Y12 Receptor

By  

Current Pharmaceutical Design, Vol. 12, Iss. 10, 2006-04 ,pp. : 1255-1259

Bentham Science Publishers

Access to resources Recommend Favorite